Key result
Multidisciplinary care integrating standardized algorithms and targeted biologics optimizes pediatric hyperinflammatory disorder management.
Why the study?
Overlapping presentations of pediatric hyperinflammatory diseases pose diagnostic challenges, where early and accurate differentiation is critical to mitigate severe complications.
This narrative review provides a comprehensive overview of diagnostic and therapeutic algorithms for pediatric hyperinflammatory diseases, emphasizing the importance of early biologic therapy and multidisciplinary care to prevent severe cardiovascular complications.
Answers are grounded in this paper and cite their sources.
May inform multidisciplinary strategies in pediatric hyperinflammation; leaves open prospective validation of outcomes.
Pediatric hyperinflammatory diseases, including Still's disease, Kawasaki disease (KD), multisystem inflammatory syndrome in children (MIS-C), and recurrent pericarditis (RP), represent a spectrum of conditions characterized by immune dysregulation and systemic inflammation. Each disorder exhibits distinct pathophysiological mechanisms and clinical features, yet their overlapping presentations often pose diagnostic challenges. Early and accurate differentiation is critical to mitigate complications such as macrophage activation syndrome (MAS), coronary artery aneurysms, and myocardial dysfunction. This narrative review explores the pathophysiology, diagnostic criteria, and management of these conditions, emphasizing the utility of advanced biomarkers, imaging modalities, and genetic testing. For Still's disease, the review highlights the transformative role of biologic therapies targeting IL-1 and IL-6 in reducing systemic inflammation and improving outcomes. In KD, timely administration of intravenous immunoglobulin (IVIG) and combination with high-dose steroids in high-risk patients is pivotal for preventing coronary complications. MIS-C, associated with SARS-CoV-2 infection, requires tailored immunomodulatory approaches, including corticosteroids and biologics, to address severe hyperinflammation and multiorgan involvement. RP management prioritizes NSAIDs, colchicine, and IL-1 inhibitors to reduce recurrence and corticosteroid dependence. The review advocates for a multidisciplinary approach, integrating standardized diagnostic algorithms and disease-specific expertise to optimize patient care. Future research directions include the identification of predictive biomarkers, exploration of novel therapeutic targets, and development of evidence-based treatment protocols to enhance long-term outcomes in pediatric inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Torre et al. (2025) conducted a review in Pediatric hyperinflammatory disorders (Still's disease, Kawasaki disease, MIS-C, recurrent pericarditis). Multidisciplinary management and biologic therapies was evaluated. A multidisciplinary approach integrating standardized diagnostic algorithms and targeted biologic therapies optimizes the management of pediatric hyperinflammatory disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: